SCHEMBL27802447

SCHEMBL27802447

NC(=O)N(Cc1cccc(-c2cccnc2)c1)c1ccc(Cl)c(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.47
S1PR1 P21453 1/20 0.44
PDK1 Q15118 7/20 0.43
MAPT P10636 1/20 0.43
MKNK1 Q9BUB5 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
CETP P11597 1/20 0.41
NAMPT P43490 1/20 0.41
PSMB5 P28074 2/20 0.40
BRAF P15056 1/20 0.40
SCN5A Q14524 1/20 0.39
SCN9A Q15858 1/20 0.39
CDK8 P49336 2/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4583491 0.92 NR1H4 (0.48) NR1H4S1PR1PDK1MAPTMKNK1
SCHEMBL27802485 0.91 MKNK1 (0.46) NR1H4S1PR1PDK1MAPTMKNK1
SCHEMBL27802487 0.90 S1PR1 (0.46) NR1H4S1PR1PDK1MAPTCETP
SCHEMBL15104092 0.84 S1PR1 (0.41) NR1H4S1PR1PDK1CDK8
SCHEMBL4582429 0.84 S1PR1 (0.46) NR1H4S1PR1PDK1MAPTCETP
SCHEMBL4581436 0.84 MAPT (0.48) NR1H4S1PR1PDK1MAPTMKNK1
SCHEMBL4581453 0.82 S1PR1 (0.47) NR1H4S1PR1PDK1MAPTCETP
SCHEMBL1790577 0.81 S1PR1 (0.45) NR1H4S1PR1PDK1MAPTCDK8
SCHEMBL27823156 0.80 PDK1 (0.42) PDK1MKNK1MKNK2NAMPT
SCHEMBL4581641 0.80 S1PR1 (0.44) NR1H4S1PR1PDK1MAPTSCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101959516-A Combination therapy comprising quinoxaline PI3K alpha inhibitors for the treatment of cancer EXELIXIS INC 2011-01-26 CN disclosed